A Phase 1/2 study of exploring the safety tolerablility and efficacy of Epacadostat in combination with Durvalumab in subjects with selected advanced solid tumors.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
October 1, 2016
End Date
June 9, 2020
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
October 1, 2016
End Date
June 9, 2020